Q-omics provides the consensus-scored RN7SL302P profile across patient tissues and cancer cell-line models. RN7SL302P expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, RN7SL302P is differentially expressed in 4, with the highest sampling consensus in STAD. Additionally, RN7SL302P RNA expression shows 6,079 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight MESO, and STAD as cancer lineages where RN7SL302P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RN7SL302P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RN7SL302P survival associations across molecular data types. RN7SL302P RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RN7SL302P RNA expression–survival associations across cancer types. High RN7SL302P expression shows unfavorable associations in MESO, SKCM, TGCT, DLBC and READ, but favorable associations in CESC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .006). Together, the overview and detailed table identify MESO as the clearest survival context for RN7SL302P RNA expression.
This table summarizes RN7SL302P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for RN7SL302P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RN7SL302P shows lower tumor expression in UCEC and KIRC and higher tumor expression in STAD and LUAD. The STAD box plot shows higher RN7SL302P RNA expression in tumor versus normal tissue (log2 FC = +0.123, t-test p = .036).
This table shows molecular features associated with RN7SL302P in patient tissues and cancer cell lines. In patient samples, RN7SL302P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
